Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

Supernus Pharmaceuticals Inc (SUPN) US$0.001

Sell:$23.45 Buy:$23.49 Change: $0.74 (3.06%)
Market closed |  Prices as at close on 24 January 2020 | Switch to live prices |
Sell:$23.45
Buy:$23.49
Change: $0.74 (3.06%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 January 2020 | Switch to live prices |
Sell:$23.45
Buy:$23.49
Change: $0.74 (3.06%)
Market closed |  Prices as at close on 24 January 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Contact details

Address:
1550 E Gude Dr
ROCKVILLE
20850-1339
United States
Telephone:
+1 (301) 8382500
Website:
https://www.supernus.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SUPN
ISIN:
US8684591089
Market cap:
$1.28 billion
Shares in issue:
52.46 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Charles Newhall
    Independent Chairman of the Board
  • Jack Khattar
    President, Chief Executive Officer, Secretary, Director
  • Gregory Patrick
    Chief Financial Officer, Vice President
  • Stefan Schwabe
    Executive Vice President - Research and Development, Chief Medical Officer
  • Padmanabh Bhatt
    Senior Vice President - Intellectual Property, Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.